Skip to main content

Advertisement

Table 1 Patient baseline characteristics by SCP statusa

From: A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

  +SCP (n = 313) −SCP (n = 420)
Mean (SD), n unless otherwise stated   
Randomized to assessment arm
 RAPID3, n (% overall) 151 (48.2) 217 (51.7)
 CDAI, n (% overall) 162 (51.8) 203 (48.3)
DAS28(ESR) 6.34 (1.07), 306 6.27 (1.07), 411
CDAI 41.41 (13.25), 307 39.30 (13.01), 416
RAPID3 16.76 (5.31), 308 15.56 (5.73), 415
TJC 16.82 (6.81), 308 15.08 (6.74), 416
SJC 12.12 (5.65), 308 12.26 (5.66), 416
PhGADA (VAS)b 6.19 (1.83), 308 6.21 (1.78), 416
PtGADA (VAS)b 6.21 (2.23), 308 5.74 (2.35), 416
Pain MDHAQ-PN (0–10 scale) 6.83 (2.07), 308 6.33 (2.16), 415
Physical function MDHAQ-FN (converted to 0–10 scale for RAPID3) 3.73 (1.82), 308 3.49 (1.92), 416
  1. Full analysis set of the PREDICT trial. For these baseline values, some patients (<3% overall) were excluded due to prohibited concomitant medications affecting their assessments. Those with valid assessments at subsequent study visits were not excluded from the overall study
  2. Abbreviations: SCP somatization comorbidity phenotype, ESR erythrocyte sedimentation rate, CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score in 28 joints, MDHAQ Multidimensional Health Assessment Questionnaire, PhGADA Physician’s Global Assessment of Disease Activity, PtGADA Patient’s Global Assessment of Disease Activity, RAPID3 Routine Assessment of Patient Index Data 3, SJC swollen joint count, TJC tender joint count
  3. aCombining the RAPID3 and CDAI arms
  4. bVisual analog scale (0–100 mm converted to cm)